Vertex Pharma stock after-hours at EUR 447.90: minus 0.62 percent
Published on 10/02/2026 at 21:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Vertex Pharma traded after-hours at EUR 447.90 at 9:41 p.m. CEST on October 2, 2026, down 0.62 percent versus the prior close at Lang & Schwarz of EUR 450.70.
Trading update
The Lang & Schwarz price was EUR 447.90, compared with the prior close of EUR 450.70. The further course of after-hours trading at Lang & Schwarz until 11:00 p.m. CEST is shown by the continuously updated real-time quote of Vertex Pharma stock.
Inaxaplin study results
In a September 22, 2026 release, Vertex Pharmaceuticals Incorporated reported Phase 2b AMPLIFIED results for inaxaplin in people with APOL1-mediated kidney disease. In the cohort with modest proteinuria, urine albumin to creatinine ratio fell 42.7 percent at Week 13 from baseline. In the cohort involving people with type 2 diabetes, the reduction was 17.3 percent.
Vertex said in the same release that inaxaplin was generally safe and well tolerated in both cohorts. The company also said it had completed enrollment in the Phase 2/3 AMPLITUDE trial and remained on track to share interim-analysis data in early 2027.
